Biophytis has filed with the FDA for authorization to initiate SARA-31 phase 3 study in sarcopenia By adminNovember 1, 2025
Biophytis annonce les prochaines รฉtapes rรจglementaires en Europe et aux รtats-Unis pour son projet COVA By adminNovember 1, 2025